This page shows the latest Sosei Heptares news and features for those working in and with pharma, biotech and healthcare.
products. Another deal – signed with Sosei Heptares this week – will see GSK collaborate on the discovery and development of a small molecule target for inflammatory bowel disease and other gastrointestinal immune
Targeting largest family of proteins in cell membranes. Sosei Heptares has enticed another big biopharma company to sign up to its G-protein coupled receptor (GPCR) drug discovery platform. ... Sosei Heptares has developed considerable expertise in GPCRs
The specific targets remain under wraps for now, although Sosei Heptares says they address metabolic and inflammatory diseases. ... The company was officially rebranded Sosei Heptares last December, but is still operating largely independently as a wholly
Pfizer's strategic-level deal with Sosei subsidiary Heptares will see the UK firm apply its technologies to engineer stabilised target GPCR proteins - selected by Pfizer - that will be used to ... biologics drugs - and will pay up to $189m per project to
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Whereas in the past the sector had “a very singular focus on amyloid”, Sosei Heptares’ chief R&D officer Malcolm Weir said he now thinks it is looking at targets “in ... Other groups, including Sosei Heptares, are working on novel ways to modify
rights to Heptares’ G protein-coupled receptor product for pain relief. ... 20. Heptares/ Sosei Group. Daiichi Sankyo. Licence. G protein coupled receptor for pain relief.
Not disclosed. Staying in oncology, AstraZeneca closed an exclusive global licence with Heptares [owned by Sosei] securing a headline value of $510m. ... Acquisition–asset. 570. Heptares [Sosei]. AZ. HTL 1071 immuno‐oncology small molecule and other
Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc.
More from intelligence
Approximately 1 fully matching, plus 3 partially matching documents found.
Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...